CDTX beat EPS expectations by 54.07%
May 08, 2025, 10:35 PM
0.00%
What does CDTX do
Cidara Therapeutics, a San Diego-based biotechnology company with 69 employees, focuses on developing targeted immunotherapies for serious diseases, including oncology and antiviral treatments. Its lead candidate, CBO421, targets solid tumors, while CD388 addresses influenza prevention and treatment.
Cidara Therapeutics (CDTX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cidara Therapeutics's actual EPS was -$1.66, beating the estimate of -$3.61 per share, resulting in a 54.07% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.